BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 7924209)

  • 1. Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime.
    Frei R; Jones RN; Pignatari AC; Yamane N; Marco F; Hoban DJ
    Diagn Microbiol Infect Dis; 1994 Mar; 18(3):167-73. PubMed ID: 7924209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicentre comparative study on the antibacterial activity of FK-037, a new parenteral cephalosporin.
    Martínez-Beltrán J; Cantón R; Liñares J; García de Lomas J; Gimeno C; Tubau F; Baquero F
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):244-52. PubMed ID: 7614970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter comparison of in vitro activities of FK-037, cefepime, ceftriaxone, ceftazidime, and cefuroxime.
    Washington JA; Jones RN; Gerlach EH; Murray PR; Allen SD; Knapp CC
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1696-700. PubMed ID: 8215286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity and beta-lactamase stability of FK-037, a parenteral cephalosporin.
    Neu HC; Chin NX; Huang HB
    Antimicrob Agents Chemother; 1993 Mar; 37(3):566-73. PubMed ID: 8460925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of cefepime tested against Bush group I beta-lactamase-producing strains resistant to ceftazidime. A multilaboratory national and international clinical isolate study.
    Jones RN; Marshall SA
    Diagn Microbiol Infect Dis; 1994 May; 19(1):33-8. PubMed ID: 7956010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group.
    Yamaguchi K; Mathai D; Biedenbach DJ; Lewis MT; Gales AC; Jones RN
    Diagn Microbiol Infect Dis; 1999 Jun; 34(2):123-34. PubMed ID: 10354863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the in vitro antimicrobial activity of cefepime compared to other broad-spectrum beta-lactams tested against recent clinical isolates from 10 Chinese hospitals. Chinese Antimicrobial Resistance Study Group.
    Xu Y; Chen M; Biedenbach DJ; Deshpande LM; Jones RN
    Diagn Microbiol Infect Dis; 1999 Oct; 35(2):135-42. PubMed ID: 10579094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin.
    Nishino T; Otsuki M; Hatano K; Nishihara Y
    Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicentre study of the in vitro activity of cefepime, a broad-spectrum cephalosporin, compared to other broad-spectrum agents.
    Bell JM; Turnidge JD;
    Pathology; 2001 Feb; 33(1):53-60. PubMed ID: 11280610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro antibacterial activity of FK037, a novel parenteral broad-spectrum cephalosporin.
    Mine Y; Watanabe Y; Sakamoto H; Hatano K; Kuno K; Higashi Y; Kamimura T; Matsumoto Y; Tawara S; Matsumoto F
    J Antibiot (Tokyo); 1993 Jan; 46(1):71-87. PubMed ID: 8436562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY Antimicrobial Surveillance Program (2005-2006).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 May; 61(1):86-95. PubMed ID: 18385000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity of a new antipseudomonal dual-action drug, Ro 25-0534.
    Jones RN; Sanchez ML
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):61-8. PubMed ID: 8026159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity profile of ceftobiprole, an anti-MRSA cephalosporin, against recent gram-positive and gram-negative isolates of European origin.
    Pillar CM; Aranza MK; Shah D; Sahm DF
    J Antimicrob Chemother; 2008 Mar; 61(3):595-602. PubMed ID: 18218646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial activity of E-1040, a novel thiadiazolyl cephalosporin compared with other parenteral cephems.
    Jones RN; Erwin ME; Barrett MS; Johnson DM; Briggs BM
    Diagn Microbiol Infect Dis; 1991; 14(4):301-9. PubMed ID: 1889181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
    Wang FD; Liu IM; Liu CY
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group.
    Jones RN; Salazar JC; Pfaller MA; Doern GV
    Diagn Microbiol Infect Dis; 1997 Dec; 29(4):265-72. PubMed ID: 9458984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro activity of FK 037 (Cefoselis), a novel 4(th) generation cephalosporin, compared to cefepime and cefpirome on nosocomial staphylococci and gram-negative isolates.
    Giamarellos-Bourboulis EJ; Grecka P; Tsitsika A; Tympanidou C; Giamarellou H
    Diagn Microbiol Infect Dis; 2000 Mar; 36(3):185-91. PubMed ID: 10729661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of gram-negative bacilli and Staphylococcus aureus.
    Tallis E; Rudensky B; Attias D; Raveh D; Schlesinger Y; Yinnon AM
    Diagn Microbiol Infect Dis; 1999 Oct; 35(2):121-6. PubMed ID: 10579092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.